Quantcast

Latest triazolam Stories

2013-11-07 23:25:12

Stonehaven demonstrates their dedication to maintaining customer satisfaction. Utilizing the latest trends in sedation has shown to soothe anxious clients, especially children. Salt Lake City, Utah (PRWEB) November 07, 2013 As a leading dental office in Utah, Stonehaven prides themselves on customer satisfaction. Anxiety and nerves are often associated with visits to the dentist, preventing many from seeking treatment they need. Utilizing the latest methods for sedation, the...

2010-12-13 17:37:00

TITUSVILLE, N.J., Dec. 13, 2010 /PRNewswire/ -- Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P., announced today that the U.S. Food and Drug Administration (FDA) has approved a revision to the dosing recommendation to include once-daily dosing of PREZISTA® (darunavir) tablets in combination with ritonavir for the treatment of human immunodeficiency virus (HIV-1) in treatment-experienced adult patients with no darunavir resistance-associated...

2009-10-22 06:00:00

REDWOOD CITY, Calif., Oct. 22 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. today announced positive results from a Phase 2 clinical trial of ARX-03, a proprietary sublingual dosage form combining an opioid, sufentanil, with a benzodiazepine, triazolam. ARX-03 is designed to address the current unmet need for a non-invasive product to provide mild sedation, anxiolysis and analgesia with rapid onset of action for the increasing number of painful and anxiety-producing office-based...

2009-10-14 06:00:00

REDWOOD CITY, Calif., Oct. 14 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. announced today that Nigel Ray has joined the company as Vice President of Business Development. In this new position, Mr. Ray will lead AcelRx's partnering efforts for its mid- and late-stage clinical products including the ARX-01 Sufentanil NanoTab PCA System, the ARX-02 Sufentanil NanoTab Breakthrough Pain Management System and ARX-03 Sufentanil/Triazolam NanoTab providing mild sedation, anxiolysis and analgesia...

2009-01-12 18:33:00

Results Show Successful Clinical Validation of Pharmacodynamic Effect REDWOOD CITY, Calif., Jan. 12 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc., an emerging specialty pharmaceutical company focused on the treatment of intermittent and acute medical conditions with an initial emphasis on pain management, today announced positive results from a Phase 1 clinical study evaluating the safety, tolerability and efficacy of the company's proprietary sublingual sufentanil (opioid) and triazolam...

2008-10-01 06:00:48

Research and Markets (http://www.researchandmarkets.com/research/370328/inhaled_cns_therap) has announced the addition of the "Inhaled CNS Therapeutics - Markets & Opportunities" report to their offering. Delivering drugs to the central nervous system presents unique challenges. But, drug developers and researchers have discovered that delivering CNS therapeutic drugs via inhalation mitigates several of these issues. The accessibility and vascular structure of the nose make it an...

2006-06-21 08:00:00

By Bill Berkrot NEW YORK -- An experimental insomnia drug being developed by Merck & Co. and Danish drug maker H. Lundbeck A/S showed promise in helping patients achieve deep sleep in small mid-stage clinical studies, the companies said on Wednesday. Statistically significant increases in deep sleep were seen with gaboxadol at all four tested doses compared to a placebo, but the drug appeared to be more effective at the higher 10 milligram, 15 mg, and 20 mg than at the lowest 5 mg dose,...

2005-12-11 09:26:18

Ambien, Lunesta and Sonata all have their pluses and minuses, study found HealthDay News -- No single sleeping pill stands out as the best, according to a U.S. review of the newer sleep aids on the market. The researchers reviewed 141 studies of the sleeping pills Sonata, Ambien, Lunesta and a Canadian brand called Imovane. These are all considered newer sleeping aids and are commonly prescribed for insomnia in place of older benzodiazepine sleeping aids such as Halcion, ProSom and Restoril....


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.